as 03-25-2025 10:37am EST
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Founded: | 1985 | Country: | United States |
Employees: | N/A | City: | MARLBOROUGH |
Market Cap: | 16.3B | IPO Year: | 1990 |
Target Price: | $84.17 | AVG Volume (30 days): | 2.6M |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 3.16 | EPS Growth: | 50.83 |
52 Week Low/High: | $60.34 - $84.67 | Next Earning Date: | 05-01-2025 |
Revenue: | $4,039,000,000 | Revenue Growth: | 1.76% |
Revenue Growth (this year): | 3.42% | Revenue Growth (next year): | 5.16% |
HOLX Breaking Stock News: Dive into HOLX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Simply Wall St.
2 days ago
Zacks
6 days ago
Zacks
7 days ago
Zacks
7 days ago
Zacks
9 days ago
Zacks
9 days ago
Zacks
12 days ago
The information presented on this page, "HOLX Hologic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.